The effect of rivaroxaban on hearing loss

Phase 2

Recruiting

• Conditions: Decreased sensorineural hearing.; Unspecified sensorineural hearing loss; H90.5

• Registration Number: IRCT20110603006699N5
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Diagnosis of SNHL by an ENT specialist
Reduction of more than 30 dB in hearing at least 3 frequencies
Body mass index between 18-30 kg per square meter
Negative pregnancy test in women of reproductive age 15-35 years
Normal coagulation tests
Normal renal function
Regular visits for follow up
Consent to enter the study

Exclusion Criteria

Previous hemorrhagic diseases such as intracranial hemorrhage
Previous coagulation diseases
History of previous thrombosis anywhere on the body
Active stomach ulcers
History of psychiatric diseases
Any previous illness or surgery on the ears
Any signs of inflammation or infection of the ear on examination
History of hearing loss
Meniere's disease
Recent vocal or compressive trauma
Underlying disease that may be the cause of SNHL, such as trauma, autotoxic drugs, infection, etc
Blood pressure higher than 180/110
Uncontrolled diabetes
Hypersensitivity reaction to corticosteroids
Taking drugs such as methadone

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pure tone audiometry Level. Timepoint: Beginning and end of the study. Method of measurement: Audiometric device.;Word recognition score level. Timepoint: Beginning and end of the study. Method of measurement: Audiometric device.